AA
AUXL

Antipodean Advisors’s AUXILIUM PHARAMCEUTICALS INC AUXL Stock Holding History

Antipodean Advisors’s Portfolio AUXL Stock Details AUXL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		– Sell
-377,000
Closed -$11.3M – 32
2014
Q3 		$11.3M Buy
+377,000
New +$7.99M 1.1% 23

Other funds holding AUXL

DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
TAL
TIG Advisors LLC New York $2.16B AUM 72.99% 1-Year Est. Return
OAM
Oxford Asset Management Oxford, United Kingdom $232M AUM 31% 1-Year Est. Return
MP
Manikay Partners New York $893M AUM 55.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Antipodean Advisors's AUXL Position: Q4 2014 in Review

Antipodean Advisors sold out of AUXILIUM PHARAMCEUTICALS INC (AUXL) in Q4 2014, closing a stake of 377,000 shares — an estimated $11.3M sold.

Antipodean Advisors first reported a position in AUXL in Q3 2014 and held it in 1 quarter. The position peaked at $11.3M in Q3 2014. 158 funds tracked by Wall St. Rank hold AUXL as of Q4 2014.

  • Antipodean Advisors reported no remaining AUXILIUM PHARAMCEUTICALS INC position as of Q4 2014 after selling out during the quarter.
  • Antipodean Advisors sold 377,000 AUXILIUM PHARAMCEUTICALS INC shares in Q4 2014, an estimated $11.3M.
  • Antipodean Advisors first reported a position in AUXILIUM PHARAMCEUTICALS INC in Q3 2014 and held it in 1 quarter.
  • Antipodean Advisors's AUXILIUM PHARAMCEUTICALS INC position peaked at $11.3M in Q3 2014.
  • 158 funds tracked by Wall St. Rank held AUXILIUM PHARAMCEUTICALS INC as of Q4 2014.

Based on Antipodean Advisors's 13F filing for Q4 2014, filed 17 Feb 2015.